Pour plus de facilité, laissez cette case cochée. Sur les appareils partagés, nous vous conseillons de vous déconnecter d'Euroquity à la fin de votre utilisation
Email

Vous allez recevoir un email pour créer un nouveau mot de passe

Localisation

Choisissez votre pays

et votre langue

Bonjour ,

Bienvenue sur votre profil personnel. Votre carte de visite professionnelle présente votre activité principale. Elle sera visible sur EuroQuity.

% complété

%

medal 1
Ce profil est validé par 1 label.

Company

ABSCINT NV

ABSCINT NV_logo
23
EQ SCORE

L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.

ABSCINT is a clinical stage molecular imaging company that develops in-vivo diagnostics based on single domain antibodies. ABSCINT focuses on the development of radiolabelled single domain antibodies for whole body molecular imaging applications.

Ganshoren, Région de Bruxelles-Capitale, Belgium

Send a message

Anglais

ABSCINT NV

Anglais

ABSCINT | Molecular Imaging Company

Patients can live healthier and longer lives when disease progression is prevented or delayed. This can only happen if patients get a timely diagnosis, which is then followed by appropriate clinical management. With the apparition of more complex and expensive therapies, the need for better diagnostic tools becomes essential. Disease specific aberrant cells, , can be detected via radiolabelled molecules by means...

See more

ABSCINT | Molecular Imaging Company

Patients can live healthier and longer lives when disease progression is prevented or delayed. This can only happen if patients get a timely diagnosis, which is then followed by appropriate clinical management. With the apparition of more complex and expensive therapies, the need for better diagnostic tools becomes essential. Disease specific aberrant cells, , can be detected via radiolabelled molecules by means of whole body molecular imaging, a method where the whole body is scanned to highlight and locate lesions where the aberrant cells resides. ABSCINT’s business model is to develop and sell single-domain antibody tracers directly to the hospitals and physicians in the field of oncology, cardiology and immunology. The tracers will be available in kit-form for an easy on-site radiolabelling and patient administration. Furthermore, business development deals with therapeutic companies will be established to use ABSCINT’s kits in clinical trials in order to monitor the efficacy of their treatment.

617K€ was already raised from investors, a 1.77 Mio € grant was obtained from the Walloon region (Belgium) with a second tranche of 1.3 Mio € which will be obtained after a go/no go decision (08/2022). Next step: GMP production of material and pivotal clinical trials  € 6 Mio € sought

Our latest news

Team member(s)

Your request has been sent
Join this organization
Your request has been sent

Our network

Your request has been sent
Join this network
Your message has been sent

Certifications

ePitches EuroQuity
218 Entities

Communities

EUROQUITY BELGIUM
EuroQuity Belgium AT THE SERVICE OF BUSINESS GROWTH The community is reserved for Belgian startups and scaleups and their partners: investors and business advisors.
922 Members

Our history

Start in 14/01/2021

  • 14/01/2021

    Signed IP agreement with VUB/VIB

  • 15/01/2021

    Seed financing series A obtained: € 215 K secured

  • 01/03/2021

    Start BioWin project

  • 03/03/2021

    Seed financing seriesB obtained: € 317 K secured

to be continued ...